to the renal function using this simple nomogram. Introducing this estimated serum creatinine-based estimated GFR (eGFR) was a giant step because it was easy to use and increased the focus on the need for correcting dosages of many drugs that were mainly cleared by the kidneys. On the other hand, this method over-or underestimated the renal function in so many cases, since it was dependent on many factors such as age, gender, race, body mass, muscle mass, food intake and a stable state of hydration and clinical situation in general. So, the method added important new information for use in safe drug-dosing, but it was not perfect even though it was closely related to a renal clearance method using an endogenous marker of kidney function (creatinine). Since then, numerous new serum (S)-creatinine-based formulas of eGFR have taken over, but we postulate that no major changes have been seen in the last 60 years, and that we still have problems with the use of estimating methods for drug dosing. In the perfect world, the eGFR always reflects the actual GFR and therefore would be a reliable/safe base for calculating a loading dose and the continuous dosing of any drug in any clinical situation, cleared by the kidney. Very often it is not, and this is discussed in the following section.
Access to an instant and exact estimate of GFR is mandatory to all clinicians treating severely ill patients and to all clinicians dosing life-saving drugs in cancer treatment and in so many other situations. Such methods are, however, rarely used (i.e., methods using more specific glomerular filtration markers). Many find the methods expensive and cumbersome. Therefore, and instead of doing the right thing, many creatinine-based methods have been developed in an attempt to improve the situation. These include algorithms based on S-creatinine and few clinical parameters with or without urine collections: creatinine clearance, Cockcroft Gault (CG), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) [2] , or algorithms based on P-creatinine in combination with P-cystatin C or P-cystatin C alone [3] . Approaches to get closer to using a golden standard methodology such as the most accurate methods using constant infusion techniques with urine collections, infusing specific filtration markers such as inulin, 51 Cr-EDTA [4] , iohexol [5] , iothalamate [6] or others are rarely used even in clinical research. We believe that this is inexpedient. These markers can all be used in much simpler settings using bolus injection, timed plasma sampling (perhaps only one), thereby obtaining quicker and much more reliable estimates of GFR.
Limitations of Estimated Creatinine Clearance and Urinary Creatinine Clearance Methods
The eGFR methods are based on correlations or linear regression models between S-creatinine, P-cystatin C or both and variable patient variables and are also based on measuring the glomerular filtration rate (mGFR), in rather heterogeneous populations. Despite high correlation quotients between eGFR and mGFR seen in many of these studies, it is questionable whether such correlations reflect a clinically useful agreement between eGFR and mGFR in different patient populations, which most often they do not [7, 8] .
The creatinine clearance method overestimates clearance due to the secretion of creatinine in tubules [9] and is not appropriate for patients with ascites and oedemas, in elderly patients with low muscle mass, or in young patients with large muscle mass or on special diets.
mGFR with an exogenous filtration marker is the most accurate, either with inulin, 51 Cr-EDTA-clearance, 99m Tc-DTPA, iohexol or iothalamate [10] , and in the clinic especially, the 51 Cr-EDTA clearance [4] and iohexol [11] methods are rather simple and cost effective to use, and have in many studies shown excellent performance and precision [10] .
Estimated Glomerular Clearance Equations versus Direct Glomerular Filtration Measurements as Endpoints in Clinical Studies
There are many controversies in the estimation methods used in the field of drug monitoring. This practice is, however, widely used and finds support in reviews [12] ; FDA actually recommends that endpoints, safety and dosing of new drugs are being validated on the basis of estimating methods [13] . We are not claiming that there are no arguments at all for using methods estimating GFR, but we do have our anxieties in this regard as argued below where we discuss drug dosing in cancer patients. Among those in favour of using eGFR, drugs were, after Effersoe, historically dosed according to the CG [14] equation with all its weaknesses. The development of better methods like the MDRD [15] equation also gave rise to problems with interpretation of drug recommendations in all but relatively healthy and stable patient populations. Using the formula does however find support. Thus, a large study by Stevens et al. [12] compared with iothalamate excretion in the urine. There were a rather good concordance with the MDRD equation compared to the CG equation in terms of iothalamate clearance, and this was tested for 15 recommended drug doses of medications cleared by the kidneys. In conclusion, they recommended that the MDRD should be used for drug dosing instead of CG until better equations were developed.
This may be true for less toxic drugs with a wide therapeutic window. However, too many errors are involved in the use of eGFR-creatinine-or cystatin C-based formulas to dose drugs, to unstable, often malnourished sarcopenic critically ill patients in the hospital wards. We exemplify this in the next section describing problems in drug dosing after guidance of eGFR in patients treated with cisplatin.
Drug Dosing in Cancer Patients
The use of eGFR methods have only sparsely been investigated in cancer patients [16] . Caution should especially be exercised when estimation methods are used in dosing of drugs affecting tubular function and creatinine secretion, giving rise to an underestimation of renal function and a risk of too low dosage of a lifesaving drug.
Calvert et al. [22] developed a simple formula for carboplatin dosing and the equation was developed with a gold standard to measure GFR; later it was adjusted with CG eGFR, giving rise to the same problems with sampling errors and overestimation as traditional eGFR methods ( Table 1 ) . Dooley et al. [17] demonstrated that the Chatelut formula overestimated the carboplatin dose, especially in men and a gender difference was present in the different formulas. Furthermore, many of the equations used to calculate carboplatin dose used older assays to determine serum creatinine, which was another source of error [18] .
Our group participated in a study where cisplatin was used for the chemotherapy (CT) of male germ cell cancer patients. The cohort was without major comorbidities and had good survival benefits. We also studied the eGFR formula's (by MDRD, Wright, CKD-EPI, and CG) [14, 15, 19, 26] influence on hypothetical carboplatin dosage, a drug much used in cancer treatment.
The level of agreement in hypothetically derived carboplatin dosages was calculated. The values after treatment were divided into cisplatin dose strata equivalent to the number of treatment cycles. MDRD offered the best bias, precision and accuracy after CT, 3 and 4 cycles. The other equations were more imprecise. In patients receiving more than 5 cycles of CT, more than 62% of the patients had an eGFR that differed from mGFR by more than 30%. If the equations were used to calculate carboplatin dosage, the doses given would generally be too high, especially when the CKD-EPI and CG equations were used. Post-CT mGFR decreased in comparison to pretreatment mGFR, a median of 9 mL/min after 3 cycles, 14 mL/ min after 4 cycles and 20 mL/min after +5 cycles. All eGFR estimates, by the MDRD, Wright and CKD-EPI equations, except for the CG equation, increased significantly after CT. During follow-up at 1, 3, and 5 years, all estimates decreased and mGFR increased significantly [27] .
New Methods for Drug Dosing
There are some hospitals where they do even better having established pharmacological or biochemistry departments that help in calculating the subsequent dosing (amount and interval) on the basis of measured plasma levels of the drug in question, typically an antibiotic. It does not appear that kidney function estimates are needed for that approach; what they are essentially doing is using the antibiotic as the filtration marker and calculating its clearance.
New methods are emerging, like kidney-on-a-chip [20, 21] where renal tubular cells have been integrated with microfluidic devices and used to measure the toxicity of an antibiotic. This has large perspectives if it is developed to act as a fast and bedside method, but still a lot of validation studies are needed before it can replace, for example, the measurement of drug concentration.
There is a potential problem with the fact that drug clearance in many of these chips are based on animal cells; drug clearance is higher in animals than in humans, giving rise to a bias in the judgement of toxicity, and human cell lines should be introduced and validated.
Conclusions
Using eGFR uncritically and as a new golden standard in planning drug dosing is often wrong and unsafe. All the pitfalls and biases behind a correct, accurate and precise eGFR must always be kept in mind and in many cases more direct methods of GFR should be considered in daily clinical practice.
